Tarsons Products
- Market cap
- ₹ 1,599 Cr.
- P/E
- 136.9x
- P/B
- 2.59x
- 52-week range
- 164.45 – 375
- ROE
- 2%
- ROCE
- 5%
- Dividend yield
- 0%
- Debt / equity
- 0.62
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
About
Tarsons Products Limited is an India-based labware company. The Company is engaged in designing, development, manufacturing and marketing of consumables, reusables and others including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies contract research organizations (CROs), diagnostic companies and hospitals. The Company is also engaged in the manufacturing of range a of labware products which helps scientific discovery and improve healthcare. The Company has developed a diverse range of labware products under the categories: consumables, reusables and others. The Company's consumables products include pipette tips, centrifuge ware, petri dishes, cryo ware and storage vials. Its reusable products include bottles and carboys, beakers, cylinders and racks. It also offers polymerase chain reaction (PCR) and cell culture products.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Tarsons Products against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)136.9 against a typical 28.7: pricier than most peers (1st = cheapest).25th of 25
- Sales growth+20.7% against a typical +21.5% from a year earlier.10th of 18
- Profit growth−180.9% against a typical +13.4% from a year earlier.15th of 16
- Share price, 3 months−4.7% against a typical −7.9%.11th of 23
- Size₹ 1,599.4 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).4th of 24
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A | Stable | 6 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 6 Apr 2026 | Reaffirmed | CARE A | — | CARE | ₹ 612.73 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 10 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 22 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 6 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 12 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 28 May 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 85 | 62 | 106 | 85 | 99 | 96 | 113 | 91 | 102 | 108 | 121 | 110 |
| Expenses | 41 | 39 | 75 | 66 | 74 | 66 | 76 | 67 | 75 | 76 | 87 | 84 |
| Operating Profit | 44 | 23 | 30 | 19 | 25 | 30 | 37 | 25 | 27 | 32 | 34 | 26 |
| OPM % | 52.2% | 37% | 28.6% | 22.1% | 25.5% | 31% | 32.9% | 27% | 26.8% | 29.2% | 28.3% | 23.6% |
| Other Income | 3 | 3 | 3 | 3 | 8 | 1 | 4 | 3 | 6 | 7 | 7 | 6 |
| Interest | 0 | 3 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 |
| Depreciation | 7 | 10 | 12 | 11 | 14 | 17 | 20 | 20 | 22 | 25 | 29 | 27 |
| Profit before tax | 39 | 14 | 17 | 6 | 15 | 8 | 16 | 3 | 6 | 8 | 6 | −1 |
| Tax % | 24.9% | 26.7% | 39.5% | 36.4% | 30.8% | 34.7% | 34.5% | 41.3% | 40.6% | 32.9% | 27.6% | 9.1% |
| Net Profit | 29 | 10 | 10 | 4 | 10 | 5 | 10 | 2 | 3 | 5 | 4 | −1 |
| EPS in Rs | 5.54 | 1.87 | 1.94 | 0.76 | 1.93 | 0.99 | 1.92 | 0.33 | 0.62 | 0.95 | 0.79 | −0.27 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 13%
- 3 Years
- —
- TTM
- 11%
- 10 Years
- —
- 5 Years
- −26%
- 3 Years
- —
- TTM
- −57%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −13%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 5%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Tarsons Products | ₹ 305.10 | ₹ 1,599 Cr. | 136.9x | 2.6x | 2% | — |
| Shivalik Bimetal Controls | ₹ 902.00 | ₹ 5,196 Cr. | 44x | 8.8x | 21.6% | 16.8% |
| Rishabh Instruments | ₹ 637.60 | ₹ 2,479 Cr. | 31.1x | 3.4x | 12% | 10.6% |
| Rolcon Engineering Company | ₹ 462.10 | ₹ 35 Cr. | 12.5x | 1.4x | 11.9% | 6.4% |
| EPIC Energy | ₹ 38.85 | ₹ 31 Cr. | 36.5x | 1.9x | 6.6% | 14.4% |
Management
- Sanjive Sehgal
- Executive Chairman of the Board, Managing Director
- Santosh Kumar Agarwal
- Chief Financial Officer, Compliance Officer, Company Secretary
- Aryan Sehgal
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.